TBX 1400

Drug Profile

TBX 1400

Latest Information Update: 07 Jul 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Taiga Biotechnologies
  • Class Stem cell therapies
  • Mechanism of Action Immunostimulants; Stem cell modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Immunodeficiency disorders
  • New Molecular Entity No

Highest Development Phases

  • Preclinical Immunodeficiency disorders

Most Recent Events

  • 13 Jun 2016 TBX 1400 receives Orphan Drug status for Immunodeficiency disorders (Severe combined immunodeficiency) in USA
  • 13 Jun 2016 Taiga Biotechnologies plans a phase I trial for Immunodeficiency disorders (Severe combined immunodeficiency) (In children) in Israel
  • 01 Jan 2016 Preclinical trials in Immunodeficiency disorders in Israel (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top